PCR based technology developed to detect HIV drug resistant virus in test samples
When first instances of HIV infection detected there were no drugs to cure or reduce the symptoms associated with virus infection. Remarkable number of people lost their lives due to uncontrolled nature of HIV infection. Much later with a continuous research efforts scientists developed drugs for HIV infection and many lives were saved. Now a days HIV infection seems like a regular fever due to the availability of good and effective drugs.
Recently many of us coming across the name called “Superbug” a bacterial strain resistance to drugs. Envision being wiped out in the healing facility with a bacterial disease and specialists can’t prevent it from spreading. But these are just bacterial infections; imagine how about a drug resistant HIV virus. While strong antiretroviral drugs exist to treat HIV contamination, the infection is a continually moving target, amassing transformations and forming into strains that are impervious to a specific antiretroviral, particularly when patients’ entrance to prescription is hindered or they don’t hold fast to a treatment regimen.
Harvard University has conceded a permit to Aldatu Biosciences, Inc., an early-arrange diagnostics improvement organization, for a novel qPCR genotyping stage that may help clinicians treating HIV to all the more rapidly decide the best medicine for every patient. This innovation addresses the significant test of medication resistance among HIV-tainted patients in asset poor zones.
The PCR technique is named as Pan-Degenerate Amplification and Adaptation (PANDAA). To recognise drug-safe infections, scientists search for key varieties in the viral genome. The test is that HIV, in the same way as other pathogens, is exceedingly polymorphic, which means the hereditary code is overflowing with slight varieties called SNPs (“clips”). Some of these SNPs present vulnerability or imperviousness to specific ARVs, while others assume diverse parts in the genome. An exceedingly touchy innovation like standard qPCR can turn up false negatives. PANDAA’s leeway, as indicated by the designers, is that it strips away diverting arrangement variety while leaving the clinically applicable SNPs in place.